Clear All
777 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Ruxolitinib Jakafi 15 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Raloxifene Hydrochloride Evista 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA Pomalidomide Pomalyst 1 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Nintedanib Ofev 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Fluorouracil Carac, Efudex topical, varies Chemotherapy Antimetabolite Pyrimidine Analog No 1970 In Use
NA Vandetanib Caprelsa 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Ponatinib Iclusig 45 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2012 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Ruxolitinib Jakafi 20 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Diethylstilbestrol DES, Stilbestrol unspecified Hormonal Therapy Estrogen Yes 1905 2000 In Use
NA Sotorasib Lumakras Multiple Chemotherapy RAS Inhibitor KRASG12C Yes 2021 In Use
NA Rucaparib Rubraca 300 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Sorafenib Nexavar 200 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET, CRAF, BRAF Yes 2005 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use
NA Testolactone Teslac 250 mg Hormonal Therapy Androgen Yes 1970 Jun 25, 2005 No Longer Used
NA Alitretinoin Panretin 0.10% Hormonal Therapy Immunomodulator Retinoic Acid Derivative No 1999 In Use
NA Erlotinib Tarceva 25 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2004 In Use
NA Dutasteride Avodart 0.5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 2002 In Use
NA Pilocarpine Hydrochloride Pilocarpine 5mg, 10mg Ancillary Therapy Miscellaneous Agent Cholinergic Agent Yes 2020 In Use
NA Bromocriptine Mesylate Parlodel Chemotherapy Dopamine Agonist Ergot Derivative Yes 1978 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Abiraterone acetate Zytiga 250 mg Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Yes 2011 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.